HHS draft 503A peptide compounding policy
Published November 4, 2026 · Coverage October 25–31, 2026, Pacific · Medium priority
On October 30, HHS announced a draft enforcement-discretion policy concerning certain peptide bulk drug substances used in section 503A compounding while the applicable bulk-substances list is developed. The notice requests written comments within two weeks after publication. HHS says the draft does not establish rights and is not binding on HHS or the public. The notice does not establish blanket permission to compound every peptide; the named substances, conditions and current status require review.
Why it matters: Pharmacies and other organizations involved in 503A compounding may need to assess whether the draft addresses substances and activities relevant to them. A draft enforcement-discretion discussion does not establish that a particular compound is approved or that every legal requirement has been met.
Suggested action: Compounding, pharmacy and legal teams can identify potentially affected materials and practices, review the complete draft and applicable requirements before changing practice, and separately decide whether to comment within the stated period.
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →